cell and gene therapy Market

The cell and gene therapy market is expected to grow from US$ 4,485.00 million in 2023 to US$ 28,050.39 million by 2031; it is anticipated to record a CAGR of 25.8% from 2023 to 2031.

Key segments that contributed to the derivation of the cell and gene therapy market analysis are services, scale, service providers, and end user.

The cell and gene therapy market, by type, the cell and gene therapy market is segmented into bifurcated into cell therapy, gene therapy. The cell therapy segment held a larger market share in 2023. Cell therapy helps treat disorders and diseases by restoring or changing certain groups of cells or providing cells to carry therapy through the body. Cell therapy forms or modifies cells outside the body before introducing into the patient. The cells might derive from the patient (autologous cells) or a donor (allogeneic cells). The growth of the cell therapy segment is attributed to the increasing number of products entering the market, the potential application of cell therapies in treating autoimmune diseases, cancer, and infectious diseases, and the high number of ongoing clinical trials.

The cell and gene therapy market, by services, the market is segmented into process development, cGMP manufacturing, regulatory services, bioassay services. The process development segment held a larger share of the market in 2023. The cell and gene therapy market is witnessing rapid growth driven by technological advancements, particularly in manufacturing and delivery services. With such advancements, cell and gene therapy developers offer expertise in developing robust and scalable manufacturing processes, ensuring high-quality product consistency, and optimizing delivery methods for specific therapeutic targets.

By type, the market is segmented into vented and non-vented. The vented segment held a larger share of the market in 2023.

The cell and gene therapy market, by scale, the market is bifurcated into pre commercial/R and D manufacturing, commercial scale manufacturing. The pre commercial/R and D manufacturing segment held a larger share of the market in 2023.

The cell and gene therapy market, by service provider, the market is divided into CDMOs, CMOs. The CDMOs segment held a larger share of the market in 2023.

The cell and gene therapy market, by end user, the market is segmented into contract research organizations, pharmaceutical and biopharmaceutical companies, academic and research institutes. The pharmaceutical and biopharmaceutical companies segment dominated the market in 2023.

The scope of the cell and gene therapy market report covers North America (the US, Canada, and Mexico), Europe (Spain, the UK, Germany, France, Italy, and the Rest of Europe), Asia Pacific (South Korea, China, Japan, India, Australia, and the Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). In terms of revenue, North America accounted for the largest market share in 2023. On the other hand, Asia Pacific region accounted for the fastest-growing global cell and gene therapy market in 2023. China is making progress in gene and cell therapy. The country has a large patient population making it an attractive market for companies developing these treatments. Several companies are working on innovative therapies for diseases such as cancer and genetic disorders in China, and the country has invested heavily in gene therapy research and development. China was the first country to approve gene therapy in 2003; since then, cell and gene therapy developments have advanced rapidly worldwide, and their therapeutic potential has soared. The government of the People's Republic of China has conducted several regulatory reforms to promote the normative development of cell and gene therapies. In addition, the presence of various market leaders operating in the segments is contributing to the market expansion, which contribute notably to the expansion of cell and gene therapy market size.

European Union (EU), Organisation for Economic Co-operation and Development (OECD), and National Library of Medicine (NLM) are a few key primary and secondary sources referred to while preparing the report on the cell and gene therapy market.